Expert Analysis

Treatment of HCV

Source: CCO Independent Conference Coverage of the 2004 Annual Meeting of The American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Treatment of HCV


Program Director: Patrick J. Lynch, MD

Faculty:

Gary L. Davis, MDAdrian M. Di Bisceglie, MD, FACPKaren L. Lindsay, MD
  • Gary L. Davis, MD
  • Adrian M. Di Bisceglie, MD, FACP
  • Karen L. Lindsay, MD

CME CREDIT INFORMATION

Release Date: 12/09/04

Expiration Date: 12/08/05


Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Registered Nurses: 3.0 Nursing CE credits

Pharmacists: 2.5 contact hours (0.25 CEUs)

Status: Please log in to view status

Begin the Expert Analysis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe new insights into factors complicating successful treatment, including genotype and ethnic group

  • Review the results of recent studies evaluating the use of FDA-approved agents, including peginterferon/ribavirin, in first-line treatment of HCV infection, as well as length of treatment with these agents

  • Evaluate the results of trials of drugs in development for treatment of HCV infection


Earn CME credit by reading the expert analysis and commentary on Treatment of HCV.

Topics covered include:

  • Extended Treatment for HCV Genotype 1
  • Shorter Treatment for HCV Genotypes 2 and 3
  • Consensus Interferon for Treatment Nonresponders
  • Maintenance Interferon for Preventing Disease Progression
  • Treatment of Acute Hepatitis C
  • Insulin Resistance and Liver Disease
  • New Drugs: Viramidine, NM283, and Others
  • 'Reefer' Fibrosis
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Pharmacist and nursing credit provided through the cosponsorship of Medical Education Collaborative and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

CCO Resources

CCO Expert Recap of data from the 2004 Annual Meeting of the American Association for the Study of Liver Diseases

CCO Expert Recap
CCO Slideset